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Abstract
Background: Rapid treatment of status epilepticus (SE) is associated with better outcomes. Diazepam
and midazolam are commonly used, but the optimal agent and administration route is unclear.
Objectives: The objective was to determine by systematic review if nonintravenous (non-IV) midazolam
is as effective as diazepam, by any route, in terminating SE seizures in children and adults. Time to sei-
zure cessation and respiratory complications was examined.
Methods: We performed a search of PubMed, Web of Knowledge, Embase, Cochrane Database of Sys-
tematic Reviews, Database of Abstracts of Reviews of Effects, American College of Physicians Journal
Club, Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health
Literature, and International Pharmaceutical Abstracts for studies published January 1, 1950, through
July 4, 2009. English language quasi-experimental or randomized controlled trials comparing midazolam
and diazepam as first-line treatment for SE, and meeting the Consolidated Standards of Reporting Trials
(CONSORT)-based quality measures, were eligible. Two reviewers independently screened studies for
inclusion and extracted outcomes data. Administration routes were stratified as non-IV (buccal, intrana-
sal, intramuscular, rectal) or IV. Fixed-effects models generated pooled statistics.
Results: Six studies with 774 subjects were included. For seizure cessation, midazolam, by any route, was
superior to diazepam, by any route (relative risk [RR] = 1.52; 95% confidence interval [CI] = 1.27 to 1.82).
Non-IV midazolam is as effective as IV diazepam (RR = 0.79; 95% CI = 0.19 to 3.36), and buccal midazolam
is superior to rectal diazepam in achieving seizure control (RR = 1.54; 95% CI = 1.29 to 1.85). Midazolam
was administered faster than diazepam (mean difference = 2.46 minutes; 95% CI = 1.52 to 3.39 minutes)
and had similar times between drug administration and seizure cessation. Respiratory complications
requiring intervention were similar, regardless of administration route (RR = 1.49; 95% CI = 0.25 to 8.72).
Conclusions: Non-IV midazolam, compared to non-IV or IV diazepam, is safe and effective in treating
SE. Comparison to lorazepam, evaluation in adults, and prospective confirmation of safety and efficacy
is needed.
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S eizures are a common medical emergency,accounting for 1%–2% of all emergency depart-ment (ED) visits, and status epilepticus (SE) exists
in approximately 6% of these encounters.1 However, the
optimal agent and route of administration for the treat-
ment of SE remain unclear. Almost 1 in 10 persons will
suffer at least one seizure in their lifetime.2 While most
seizures are self-limited and short, every year 120,000 to
200,000 people have prolonged convulsions or rapidly
recurrent convulsions without interval recovery, and
these patients in SE have a true medical emergency.3,4
SE is associated with high morbidity and mortality and
contributes to 55,000 deaths each year in the United
States.5–8 Common complications of SE include aspira-
tion, anoxic brain injury, cardiac instability, metabolic
and autonomic dysfunction, and direct neuronal
damage.9–16
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Although clinical outcome in SE is primarily deter-
mined by the underlying etiology that caused the sei-
zure, persistent seizure activity is associated with worse
outcomes across the spectrum of precipitating condi-
tions.16–19 In otherwise benign epilepsy, refractory SE
can still be fatal or result in neuronal injury and chronic
brain damage. In SE resulting from acute trauma or
stroke, persistent ictal activity is associated with
increased secondary neuronal cell death and worse out-
comes.20 Although duration of seizure is associated
with higher mortality and worse neurologic recovery in
survivors in clinical studies, these data do not provide
rigorous proof of causality. However, studies of experi-
mental SE in animal models directly demonstrate that
neuronal loss increases with duration of seizure and
that kindling effects from persistent seizures are epilep-
togenic.19,21 Experimental status models also show that
the effectiveness of anticonvulsant medications to ter-
minate seizures rapidly decreases as the time between
the start of convulsions and drug administration length-
ens.22 If seizures are not terminated quickly, escalating
doses of benzodiazepines are required to achieve sei-
zure cessation, and seizures eventually become entirely
refractory to anticonvulsant therapy.23
Benzodiazepines have been the first-line treatment of
SE for the past 30 years, but the optimal drug and the
best route of administration for seizure control outside
of the hospital setting, or without intravenous (IV)
access, remains unclear. Lorazepam is a clinical stan-
dard for initial treatment of SE in EDs.24,25 While
shown to be safe for use by paramedics, lorazepam has
a relatively short shelf life without refrigeration, limit-
ing its practicality in the prehospital setting.26 Further-
more, lorazepam is only effective when given IV, and
establishing IV access can be challenging, if not impos-
sible, in convulsing patients.26–28 Diazepam is frequently
used for treatment of SE, because it can be delivered
either intravenously or rectally.26,27 However, the effec-
tiveness of diazepam in terminating seizures is thought
to be inferior to that of other benzodiazepines, espe-
cially when given rectally.25 Additionally, diazepam is
suspected to cause more complications than other ben-
zodiazepines because of the risk for prolonged sedation
and respiratory depression.26,29
Midazolam is rapidly absorbed after intramuscular
(IM) injection, does not require refrigeration, and is less
expensive than lorazepam.30 Requiring IV access before
benzodiazepine administration may unnecessarily delay
treatment of SE, placing the patient at risk, even when
done in the ED. Non-IV midazolam administration for
treatment of SE is an attractive idea, but there are few
studies of its efficacy and safety.31 A recent Cochrane
Review explored benzodiazepine treatment of pediatric
SE and included many different medication strategies.32
Important secondary outcomes, including time required
for administration of medication and time to therapeu-
tic effect, were not described, and the review did not
include studies addressing out-of-hospital management
of SE.
This meta-analysis compares the use of non-IV midazo-
lam to that of diazepam in the treatment of seizures. The
specific objective was to determine the efficacy, rapidity,
and safety of terminating seizures with non-IV midazo-
lam, compared to either IV or non-IV diazepam, as an ini-
tial emergency treatment in pediatric and adult patients
with SE.
METHODS
Data Sources and Search Strategy
A systematic review of the literature was conducted to
identify studies comparing the use of non-IV midazolam
to IV or non-IV diazepam in treating SE in pediatric
and adult patients. For the purposes of this analysis,
seizures lasting longer than 5 minutes are defined as
SE, as has been suggested elsewhere.26,33 The following
electronic databases were searched: PubMed, Web of
Knowledge, Embase, all evidence-based medicine
reviews (includes Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects,
American College of Physicians Journal Club, and
Cochrane Central Register of Controlled Trials), the
Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL), and International Pharmaceutical
Abstracts. All studies published or in press between
January 1, 1950, and July 4, 2009, were considered.
Only reports published in English were included. The
majority of articles were retrieved from PubMed and
Web of Knowledge using a Boolean search strategy
(Appendix 1). In addition to these automated searches,
we conducted a hand search of bibliographies of key
articles and abstracts presented at several major scien-
tific conferences in 2006 through 2008. These included
the annual meetings of the American College of Emer-
gency Physicians, the American Neurological Associa-
tion, the National Association of EMS Physicians, and
the Society for Academic Emergency Medicine. Finally,
references of key review articles were hand searched
for other relevant articles.
Selection Criteria
Two reviewers (CS, RS) evaluated each full-text article
and determined exclusions based on a priori criteria to
ensure the comparability of the groups and to allow for
pooling of results. These criteria excluded any study
that did not compare diazepam to non-IV administra-
tion of midazolam as a first-line treatment for SE, ani-
mal studies, any study design other than randomized
controlled or quasi-experimental, and any study that
used diazepam or midazolam for sedation or prevention
of seizures (Figure 1). Initial disagreements between
reviewers regarding study inclusion were resolved by
consensus.
Data Extraction and Quality Assessment
Studies that met our preliminary selection criteria were
further evaluated by two independent reviewers (CS,
JM) using the Consolidated Standards of Reporting Tri-
als (CONSORT) Quality Scale and the Randomized Con-
trolled Trial (RCT) Checklist.34 The CONSORT Quality
Scale has been shown to be useful in determining the
methodologic quality of randomized clinical trials in a
standardized format.34 The 30-point scale assigns points
for studies that report key concepts on randomization,
allocation concealment, repeatability of observations,
etc., and serves as a balance to the quality of writing to
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judge the strength and validity of findings. An a priori
threshold score of at least 20 was established for inclu-
sion. The RCT Checklist serves as a way to abstract
data on specific interventions and to further assess key
components of study design.
The following variables were extracted from the stud-
ies: type of study design, definition of SE, types of com-
plications reported, absolute numbers of patients in the
diazepam and the midazolam groups that had seizure
activity terminated, route of administration, and dosage
of drug administered.
Data Analysis
Study inclusion agreement between investigators was
evaluated by kappa statistics. Pooled risk ratios were
determined using both the Mantel-Haenszel fixed
effects and DerSimonian and Laird random-effects
models.35 Data were stratified into two subgroups, one
comparing IV diazepam versus non-IV midazolam, and
the other comparing non-IV diazepam to non-IV mi-
dazolam. Where study data were available, we assessed
the mean differences in times between initial assess-
ment and drug administration and between drug
administration and cessation of seizure activity based
on route of administration. A fixed-effects model was
used to pool times across studies.
Heterogeneity within the group was assessed using
Cochran’s Q-test and I2 statistic, which measures the
degree of variation among studies.36 Begg’s test and a
visual inspection of the funnel plot were conducted to
evaluate publication bias. All statistical tests were two-
sided. Stata version 10.0 (StataCorp., College Station,
TX) and Review Manager 5.0 (RevMan, Copenhagen,
Denmark; The Nordic Cochrane Centre, The Cochrane
Collaboration, 2008) were used to conduct the analyses.
A meta-influence analysis was conducted to statistically
omit one study at a time to determine the effect on the
overall pooled estimate. A sensitivity analysis was per-
formed to assess the effect of removing the most influ-
ential study from the pooled subgroup results.
RESULTS
Search and Study Characteristics
The initial literature search yielded 251 references, of
which 44 met preliminary selection criteria for inclusion
within the meta-analysis (Figure 1). Four authors were
contacted to clarify the comparability of groups, to
obtain more data, or to clarify definitions of SE. Thirty-
eight articles were excluded because trial design was
not randomized or controlled (n = 6); data included
were not original (n = 5); there was no comparison
group (n = 7); acute SE was not described (n = 7); the
two drugs chosen for this review were not utilized
(n = 5); and the CONSORT score was <20 (n = 8).34 The
kappa for interrater reliability for inclusion into the
study was 0.95.
The characteristics of the six studies included studies
containing 774 subjects are shown in Table 1,37–42 and
all are RCTs. Although the intent of our analysis was to
include all age groups, all of the studies meeting the
selection criteria happened to be studies of children
and young adults. Five studies included children only;
one study included children and adults; however, the
oldest subject was 22 years old.42 Routes of medication
administration included IV and rectal (PR) diazepam
and buccal, intranasal (IN), and IM midazolam. Dosing
of medications varied slightly among studies: diazepam
0.2–0.3 mg ⁄ kg IV or 0.5 mg ⁄ kg PR or midazolam
0.2 mg ⁄ kg IM and IN or 0.5 mg ⁄ kg buccal. One study
used fixed doses of PR diazepam (10 mg) and buccal mi-
dazolam (10 mg).42 The determination of seizure cessa-
tion was clinically based and used varying definitions
based on time until convulsion stoppage and ⁄ or
absence of seizure recurrence. Some studies included
prolonged simple partial or focal convulsions.37,39,41,42
Despite these clinical and methodologic differences,
there was no significant statistical heterogeneity in
pooled analysis of all included studies (I2 = 0%,
Figure 2).
Seizure Cessation
Midazolam, by any route, was superior to diazepam, by
any route, in achieving seizure cessation in pooled anal-
ysis (relative risk [RR] = 1.52; 95% confidence interval
[CI] = 1.27 to 1.82, n = 6, number needed to treat
[NNT] = 7; Figure 2).
Three37–39 studies of 146 subjects compared IM or
IN midazolam to IV diazepam. In pooled analysis, there
251 Citations:
62 PubMed, 124 Web of Knowledge, 15 
Embase, 20 All EBM reviews, 16 CINAHL, 14 
International Pharm Abstracts
44 Potentially relevant 
articles for full text review
14 Full text articles screened in detail
CONSORT Checklist for quality applied
6 Articles included for 
pooled analysis
8 Articles excluded for not 
meeting quality criteria 
(CONSORT score <20)
30 Articles excluded for: not RCT (6), not 
including original data (5), no comparison 
group (7), not being acute status 
epilepticus (7), and for not comparing the 
two medications (5)
157 Articles excluded after 
screening of titles and 
abstracts
Figure 1. Search strategy for articles reviewed for meta-analy-
sis. CONSORT = Consolidated Standards of Reporting Trials;
CINAHL = Cumulative Index to Nursing and Allied Health Litera-
ture; EBM = evidence-based medicine; RCT = randomized
controlled trial.
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is no apparent difference between non-IV midazolam
and IV diazepam in achieving seizure cessation
(RR = 0.79; 95% CI = 0.19 to 3.26; Figure 3). Statistical
heterogeneity of this subgroup of studies was very low
(I2 = 0%).
Three40–42 studies of 628 subjects compared rectal
diazepam to buccal midazolam. Buccal midazolam is
more successful in achieving seizure cessation
(RR = 1.54; 95% CI = 1.29 to 1.85; I2 = 0%; NNT = 6).
Time to Administration and Time to Seizure
Cessation
Early treatment of SE is likely to be most successful
and relies on the time intervals of seizure onset to med-
ical contact, medical contact to drug administration,
and drug administration to therapeutic effect. These
time intervals are separately evaluated when reported
by individual studies. No studies reliably report the time
from seizure onset to medical contact. Two37,38 studies
demonstrate non-IV midazolam was administered
2.46 minutes (95% CI = 1.52 to 3.39 minutes) quicker
than IV diazepam to seizing patients. Non-IV midazolam
and IV diazepam were similar in the time between drug
administration and seizure cessation in three37–39 stud-
ies (mean difference = 0.68 minutes, 95% CI = )0.03 to
1.39 minutes).
Respiratory Complications
Respiratory complications were rarely reported. In
five38–42 studies of 750 subjects only five instances of
respiratory depression requiring intubation or ventila-
tory support (0.7%) were described, and these all came
from a single study of non-IV benzodiazepines.40 There
is no apparent difference between the safety of midazo-
lam and diazepam (RR = 1.49; 95% CI = 0.25 to 8.72;
Figure 4). Causes of respiratory depression were
Figure 2. Diazepam versus midazolam in failure to achieve seizure cessation (all routes of administration). IV = intravenous;
IM = intramuscular; IN = intranasal; M-H = Mantel-Haenszel; PR = per rectum.
Table 1










Chamberlain et al., 199737 24 0 months–18 yr 0.3 mg ⁄ kg IV 0.2 mg ⁄ kg IM Seizing >10 minutes
Lahat et al., 200038 52 6 months–5 yr 0.3 mg ⁄ kg IV 0.2 mg ⁄ kg IN Seizing >10 minutes
Mahmoudian et al., 200439 70 2 months–15 yr 0.2 mg ⁄ kg IV 0.2 mg ⁄ kg IN Seizing at arrival to ED
McIntyre et al., 200540 219 6 months–15 yr 0.5 mg ⁄ kg PR 0.5 mg ⁄ kg buccal Seizing at arrival to ED
Mpimbaza et al., 200841 330 3 months–12 yr 0.5 mg ⁄ kg PR 0.5 mg ⁄ kg buccal Seizing at arrival to ED
or >5 minutes
Scott et al., 199942 79 5–22 yr 10 mg PR 10 mg buccal Seizing >5 minutes
CONSORT = Consolidated Standards of Reporting Trials; IM = intramuscular; IN = intranasal; IV = intravenous; PR = per rectum.
Figure 3. IV diazepam versus non-IV midazolam in failure to achieve seizure cessation. IV = intravenous; IM = intramuscular;
IN = intranasal; M-H = Mantel-Haenszel.
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described as multifactorial, but further detail was not
provided.
Sensitivity Analysis
For each outcome, removing individual studies did not
affect pooled risk ratios or measurements of statistical
heterogeneity. There is also no apparent bias intro-
duced by dose of medication, length of seizure required
for inclusion, or inclusion of nongeneralized seizures.
Outcomes were also analyzed using a random-effects
model, with no meaningful effect on the results.
A more broad pooled analysis including the eight
studies with CONSORT scores between 15 and 19
yields similar results to all outcomes:27,43–49 overall suc-
cess (RR = 1.50; 95% CI = 1.30 to 1.73, n = 14), IV diaze-
pam versus non-IV midazolam (RR = 0.90; 95%
CI = 0.48 to 1.68, n = 5), or PR diazepam versus buccal
midazolam (RR = 1.51; 95% CI = 1.26 to 1.80, n = 4). Mi-
dazolam appears to be associated with fewer respira-
tory complications in this expanded group (RR = 1.74;
95% CI = 1.23 to 2.46, n = 13, I2 = 69%); however, this
result is biased by a single study,46 and exclusion
resulted in no safety difference between the two medi-
cations (RR = 1.31; 95% CI = 0.88 to 1.95, n = 12,
I2 = 0%).
Visual inspection of funnel plots shows no obvious
signal of asymmetry, which suggests lack of significant
publication bias; this is limited due to the small num-
bers of studies included. Begg’s test was marginal, but
not statistically significant (p = 0.0724).
DISCUSSION
This pooled meta-analysis of all published data from
774 subjects in six37–42 studies supports the use of mi-
dazolam by non-IV routes as a favorable alternative to
diazepam in the initial treatment of SE. Midazolam, by
any route, achieved seizure cessation more often than
diazepam, by any route (RR = 1.52; 95% CI = 1.27 to
1.82). This finding is even more apparent when compar-
ing non-IV administration of diazepam and midazolam.
The superior efficacy of midazolam compared to diaze-
pam likely reflects more favorable pharmacokinetics.
Erratic absorption of rectal diazepam often results in
low or delayed plasma peak drug concentrations,
whereas IM and IN midazolam have a more consistent
and higher bioavailability of 87 and 55%, respectively,
with a short time to peak concentration.29
Rapidity of seizure cessation is also a clinically impor-
tant measure of performance that depends on both the
speed of administration and the onset of action. Earlier
termination of seizure reduces the risk of complications
due to convulsions, reduces neuronal injury, and is
associated with decreased mortality. Rapid termination
may also prevent kindling effects, where seizures
become more refractory to treatment and risk of recur-
rence increases as the duration of convulsions
increases.19 Reliance on the IV route for benzodiazepine
administration can be an important obstacle to rapid
treatment of SE, because of difficulty or delay in obtain-
ing IV access in a convulsing patient. As a result, our
Figure 4. Respiratory complications requiring intervention (assisted ventilations, endotracheal intubation). IV = intravenous;










No seizure activity within 5 minutes 23 Randomized Yes (11 partial motor) 0 57
No seizure activity within 5 minutes;
up to 10 minutes considered delayed
success
24 Randomized No 100 77
No seizure activity within 10 minutes 22 Randomized Yes (6 simple partial) 21 39
No seizure activity within 10 minutes and
no recurrent seizure within 1 hour
27 Randomized Yes (5 partial included were
protocol violations)
35 72
No seizure activity within 10 minutes and
no recurrent seizure within 1 hour
28 Randomized Yes (61 focal) 72 4
Seizure cessation within 10 minutes 26 Randomized Yes (17 complex partial,
10 myoclonic)
0 100
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meta-analysis appears to favor non-IV midazolam, as its
time to administration was more than 2 minutes faster
and seizure cessation less than 45 seconds slower than
that of IV diazepam.
Respiratory depression is an expected and accepted
side effect of benzodiazepine medications, and this
meta-analysis suggests that midazolam is as safe as
diazepam with regard to respiratory complications.
Overall, 0.8% (3 ⁄ 375) of pediatric patients in this analy-
sis receiving diazepam experienced complications,
which is much less than the 10.3% previously observed
with diazepam in a trial of the prehospital treatment of
SE in adults.26 Midazolam was associated with risk of
respiratory complications in children similar to that
found with diazepam (0.5%, 2 ⁄ 375). Respiratory depres-
sion in patients treated for SE can be a complication of
either continued seizures or an adverse medication
effect. At least in the prehospital setting, failure to
treat seizures is associated with much higher rates of
respiratory complications. Twenty-two percent of pla-
cebo-treated patients in a prehospital trial of SE suf-
fered a respiratory complication related to ongoing
seizure.26
Current clinical practice does not reflect the findings
that non-IV midazolam is a safe and effective treat-
ment for SE. There are no consensus guidelines
addressing prehospital treatment of SE, and many
large agencies rely solely on diazepam or allow only
restricted use of midazolam. Published professional
guidelines for SE management rely on lorazepam or
diazepam and emphasize IV administration.50–53 Only
the Royal College of General Practitioners acknowl-
edges the role of buccal midazolam for use in the
prehospital environment, but even in that guideline
rectal diazepam is preferred.52 Recent surveys of
parents and practitioners show a growing acceptance
of IN and buccal midazolam over PR diazepam, but
widespread adoption has not yet occurred.54,55 This
analysis, in conjunction with previously published sys-
tematic reviews,32,56 may inform the development of
future evidence-based guidelines. However, further
prospective clinical trials are ultimately needed to con-
firm the efficacy and safety of non-IV midazolam in
the treatment of patients with SE, especially in the
adult population.
LIMITATIONS
As with all meta-analyses, the primary limitations of
this study are those of the source data. The studies
included here are relatively small and contained differ-
ences in treatments, routes of medication administra-
tion, medication doses, outcome definitions, and
inclusion criteria. However, the pooled results demon-
strated low statistical heterogeneity, suggesting that
comparisons are valid. Given the small numbers of
studies included, the visual inspection of the funnel plot
and measure of statistical heterogeneity should be
interpreted with caution.57–59 A minimal I2 does not
guarantee homogeneity, but does provide evidence that
there was no observed heterogeneity. Our finding of
I2 = 0% is consistent with many previously published
Cochrane reviews.36
Adults were virtually unrepresented in the included
studies, and extrapolation of these results to the adult
population should be done with caution. Future trials
specifically targeting adult populations are required to
confirm these findings. Studies also used differing defi-
nitions of adverse events, which were infrequent. How-
ever, this analysis is underpowered to detect
differences in complication rates. Although a rigorous
search strategy was employed, we did not attempt to
identify or analyze non–English language studies. Com-
parisons with other anticonvulsants are lacking and
were not identified or included in this meta-analysis.
Despite these limitations, the effects identified here
appear robust given the magnitude of the findings and
the rather small CIs. Prospective confirmatory investi-
gation, however, is warranted.
CONCLUSIONS
Published data support the efficacy and safety of nonin-
travenous routes of administration for midazolam,
when compared to diazepam administered via any
route in treating patients with status epilepticus, in the
doses studied. Midazolam has characteristics that may
make it an optimal choice for the treatment of seizing
patients.
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Appendix A: Boolean Search Strategy
Date of Original Search: August 20, 2008
Search updated July 4, 2009
PICO: In pediatric and adult patients with status epilep-
ticus, is the administration of non-intravenous midazo-
lam versus any route of diazepam more effective in
ceasing seizures?
Exclusion Criteria
1. Any study that does not compare diazepam to mi-
dazolam as a first-line treatment for status epilepti-
cus.
2. Animal studies.
3. Studies that are not randomized controlled trials or
quasi-experimental studies.
4. Any study that uses diazepam or midazolam as seda-
tion, or prevention of seizures.
Search Strategy
PubMed (62) 26 pulled for full text
(‘‘Seizures’’[MeSH] OR ‘‘status epilepticus’’ [MeSH)
AND (‘‘diazepam’’[MeSH Terms] OR ‘‘diazepam’’[All
Fields]) AND (‘‘midazolam’’[MeSH Terms] OR ‘‘midazo-
lam’’[All Fields])
EMBASE (15, all duplicates)
All EBM Reviews (Cochrane, ACP Journal Club) (20
titles, 13 full texts pulled)
CINAHL (16, all duplicates)
International Pharmaceutical Abstracts (14, all dupli-
cates)
Web of Knowledge (124) (5 full texts)
Hand search of review article bibliographies: all dupli-
cates
TOTAL FULL TEXTS REVIEWED = 44
Total INCLUDED = 6
Stratified by buccal versus intranasal versus intramus-
cular midazolam and rectal versus intravenous diaze-
pam
Appendix B: Funnel Plot
Funnel plot for Figure 2 (diazepam vs. midazolam in failure to
achieve seizure cessation). Kendall’s rank correlation (Begg’s
test) = 0.77, p = 0.0724. As a comparison, the linear correlation
(Egger’s Test) = 0.27, p = 0.24.
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